
Xenon Pharmaceuticals submitted an FDA New Drug Application for azetukalner, a KV7 potassium channel opener, as adjunctive therapy for focal seizures in epilepsy.
Benjamin Greenberg, MD, presents his lecture titled, "Emerging Therapies Across the Disease Spectrum" as part of the 2020 CMSC Virtual Annual Meeting.
For more coverage from CMSC 2020,
To register for the 2020 CMSC Virtual Annual Meeting, May 26-29, 2020,
To complete the evaluation and claim credit, go to




